Show simple item record

dc.contributor.authorAndre, T
dc.contributor.authorSaunders, Mark P
dc.contributor.authorKanehisa, A
dc.contributor.authorGandossi, E
dc.contributor.authorFougeray, R
dc.contributor.authorAmellal, NC
dc.contributor.authorFalcone, A
dc.date.accessioned2020-01-29T15:17:55Z
dc.date.available2020-01-29T15:17:55Z
dc.date.issued2020en
dc.identifier.citationAndre T, Saunders M, Kanehisa A, Gandossi E, Fougeray R, Amellal NC, et al. First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. Future Oncol. 2020;16(4):21-9.en
dc.identifier.pmid31914811en
dc.identifier.doi10.2217/fon-2019-0786en
dc.identifier.urihttp://hdl.handle.net/10541/622708
dc.description.abstractTrifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine. Encouraging antitumor activity of first-line TT + bevacizumab (TT-B) has been observed in a Phase II study in patients with unresectable metastatic colorectal cancer ineligible for combination oxaliplatin- or irinotecan-based therapy. Here, we describe the design of SOLSTICE (NCT03869892), an open-label, Phase III trial in unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy. The 854 patients were randomized 1:1 to receive first-line TT-B versus capecitabine + bevacizumab. The primary objective is to demonstrate superior progression-free survival with TT-B over capecitabine + bevacizumab. The first patient was enrolled in March 2019.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/fon-2019-0786en
dc.titleFirst-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study designen
dc.typeArticleen
dc.contributor.departmentSorbonne Universite & Saint-Antoine Hospital, Paris, Franceen
dc.identifier.journalFuture Oncologyen
dc.description.noteen]
refterms.dateFOA2020-02-03T15:48:51Z


Files in this item

Thumbnail
Name:
31914811.pdf
Size:
1.413Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record